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to examine health and cost burden of HPV-related diseases to understand the potential 
impact of introducing HPV vaccine. OBJECTIVES: We aimed to evaluate the long-
term health and cost burden associated with cervical cancer, cervical intraepitherial 
neoplasia (CIN) and genital warts from health-care provider perspective in Thailand. 
METHODS: We developed a state-transition Markov model to simulate the epidemi-
ology of stages of cervical cancer, CIN and genital warts in a hypothetical cohort of 
100,000 12-year-old girls. Costs included diagnosis and treatment costs of HPV 
related diseases. Probabilities at each chance node in the model were derived from the 
Thailand health-care context. RESULTS: The highest incidence of CIN and genital 
warts was observed among women aged 20–30 years. For cervical cancer, the highest 
incidence was observed among women aged 45–55 years. Death rate was estimated 
at 2%, 8%, 84%, and 94% for cervical cancer stage IA1, IA2-IIA, IIB-IVA, and IVB, 
respectively. The estimated mean direct cost per patient with cervical cancer stage IA1, 
IA2-IIA, IIB-IVA, IVB, CIN1, CIN2/3 and genital warts were US$1277, US$3020, 
US$12,506, US$10,019, US$167, US$1551, and US$111, respectively. The overall 
lifetime costs were estimated at US$26.7 million for a cohort of 100,000 women, 
which corresponded to approximately US$132.0 million for the current entire cohort 
of 12-year-old girls in Thailand. CONCLUSIONS: HPV- related diseases impose 
signiﬁ cant health and cost burden in Thailand. The potential impact on HPV-related 
diseases of a national immunization program with HPV vaccine should be examined 
to inform the policy discussions around the HPV vaccination program in Thailand. 
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OBJECTIVES: Hypersensitivity reactions have been reported in Oxaliplatin for the 
treatment of advanced colorectal cancer (mCRC). The reported incidence of hyper-
sensitivity reactions (HSRs) is approximately 12%, with 1–2% of patients developing 
grade 3 or 4 in severity which may postpone length of stay and incurred extra cost 
for the treatment of hypersensitivity reactions. METHODS: This is a retrospective 
observational study. Medical records of hospitalized patients with mCRC, who treated 
with FOLFOX regimen and occurred mild to severe HSRs were identiﬁ ed and 
reviewed by oncology pharmacist from January 2004 to February 2010. Direct 
medical cost for the treatment of HSRs and the extra days of hospitalization were 
calculated. We compared the difference of direct medical cost for patients whose 
oxaliplatin was discontinued (group A) and those oxaliplatin was continued (group 
B) for treating mCRC after the computer detected patients’ allergy and the signal was 
appeared on the screen of physician-order-entry-system. Student t test was used for 
data analysis. RESULTS: A total of 442 patients with the diagnosis of mCRC and 
had reported moderate to severe HSRs during the treatment of FOLFOX regimen 
through our computerized decision supporting system (patients allergy history alert 
system) were included in this study. Twenty-four of 442 patients reported mild to 
severe hypersensitivity reactions caused by oxaliplatin. The total direct medical costs 
for 24 patients were NT$864,352 dollars. The direct medical cost to manage HRSs 
in group A was higher than that in group B. CONCLUSIONS: Oxaliplatin induced 
severe hypersensitivity reaction is scare, but it may cause an extra direct medical costs 
if it is appearance. To develop a computerized alert signal is helpful and is likely to 
save costs. 
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OBJECTIVES: Oncotype DX is a molecular diagnostic assay that measures quantita-
tive expression of 21 genes within a breast tumor sample. The result is reported as a 
recurrence score (RS) that correlates with the risk of 10-year recurrence. The potential 
cost impact on chemotherapy treatment and an exploratory cost utility analysis were 
undertaken from the Australian health-care system perspective. METHODS: Input on 
the proportion of patients treated with chemotherapy and treatment regimens were 
obtained from an expert panel and a supplementary survey of Australian clinicians 
(oncologists and surgeons, n = 12). Data on the proportion of patients who would 
forgo chemotherapy based on knowledge of the RS and the incidence and cost of 
adverse events were obtained from published literature. RESULTS: The clinician input 
indicated that 33% of node negative and 84% of node positive women receive adju-
vant chemotherapy on average. The most common treatments for node-negative 
patients were AC (anthracycline and cyclophosphamide) (77%) and FEC100 (ﬂ uoro-
uracil, epirubicin and cyclophosphamide) (16%) and for node-positive patients FEC-D 
(FEC plus docetaxel) (54%), AC + paclitaxel (26%) and TAC (docetaxel plus AC) 
(14%). Published switch rates away from chemotherapy are 20% for node negative 
and 24% for node positive patients. The cost saving due to a reduction in chemo-
therapy was estimated to be A$2264 per woman tested. After consideration for the 
cost of the assay (A$4200) and a published utility rate of 0.5, a A$/QALY gain was 
estimated at A$9986. CONCLUSIONS: Knowledge of the Oncotype DX RS has a 
cost-offset due to the reduction in chemotherapy and is likely to be cost-effective. 
These beneﬁ ts reﬂ ect the quality of life and survival beneﬁ ts of a more targeted 
approach to treatment decision-making. Further analysis is warranted to include the 
potential costs of relapse avoided by use of the assay and any patient indirect costs in 
Australia. 
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BACKGROUND: Breast cancer represents a signiﬁ cant burden of illness worldwide. 
Cost of cancer management is a key policy concern. The adoption of 21-gene breast 
cancer recurrence score (RS) was projected to be cost-effective. OBJECTIVES: To 
assess cost-beneﬁ t of the 21-gene RS for lymph node negative, estrogen receptor posi-
tive early-stage breast cancer (ESBC) in Singapore from a patient’s perspective. 
METHODS: We adopted a validated Markov model to calculate the cost implications 
of RS for an early-stage breast cancer patient. The probability of individual’s risk of 
recurrence, chemotherapy beneﬁ ts and decision impact of RS were derived from exist-
ing studies. The model accounted for both direct and indirect costs associated with 
adjuvant chemotherapy. Direct costs included chemotherapy drugs, supportive care 
drugs, administration, and management of adverse events adjusted by incidence, and 
cost of recurrence. Indirect costs included productivity loss during chemotherapy and 
distant recurrence. Chemotherapy regimen distribution and costs were obtained from 
medical oncologists at a private and a public cancer centers in Singapore. RESULTS: 
The pretest probabilities of risk of recurrence per woman as low, intermediate or high 
were 49.8%, 30.3%, and 19.9%, respectively. The average direct potential savings 
per patient tested in Singapore Dollars (SGD) for chemotherapy drug, supportive care, 
management of AE and administration were $2942, $1077, $169, and $1340, respec-
tively. Per patient saving from productivity loss during treatment was $468. At manu-
facturer price, the model projects immediate realized savings of $430 with the 
adoption of the RS. The model also projects $1331 direct savings, and $2418 indirect 
savings from preventing distant recurrence. Multiple sensitivity analyses demonstrate 
the robustness of the savings with adoption of RS under a variety of conditions. 
CONCLUSIONS: For women with ESBC in Singapore, the RS is a cost-saving treat-
ment decision tool. 
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OBJECTIVES: Two human papillomavirus (HPV) vaccines currently exist: a bivalent 
targeting oncogenic high-risk HPV-16/18 and a quadrivalent targeting high-risk HPV-
16/18 and low-risk HPV-6/11. Based on data in their respective trials, the bivalent 
vaccine is likely to have higher efﬁ cacy against non-vaccine oncogenic HPV-types 
(cross protection). The quadrivalent has an additional effect against genital warts. The 
differences in the annual impact of both vaccines on precancerous lesions, genital 
warts (GW) and cervical cancer (CC) were evaluated. METHODS: A static prevalence-
based model was developed, which estimates the differences in lesions, GW, CC, and 
costs prevented between the two vaccines over a one-year period at steady state (i.e., 
when all women are vaccinated). The base case analysis was performed from a health-
care payer’s perspective, including only National Health Insurance covered costs. In 
addition, an analysis from a societal perspective was performed, including also indirect 
costs and out-of-pocket payments. Epidemiological and cost data were obtained from 
published sources. Efﬁ cacy ﬁ gures were based on the latest results from each vaccine’s 
respective clinical trial. Univariate sensitivity analyses were conducted, in which 
parameters were varied 20% up and down from the baseline value. RESULTS: Under 
this model, the bivalent vaccine would result in an additional reduction of 1486 
ASCUS; 1768 CIN1; 1230 CIN2/3 and 166 CC cases per year, while the quadrivalent 
vaccine would result in an additional 7726 GW cases prevented per year. The addi-
tional annual costs averted with the bivalent vaccine was estimated at US$ 1.3 million 
and US$ 1.9 million from a health-care payer’s and societal perspective, respectively. 
This outcome is most sensitive to cross protection ﬁ gures. CONCLUSIONS: Vaccina-
tion with the bivalent vaccine is expected to have a higher impact than the quadrivalent 
vaccine on the prevention of precancerous lesions and CC in Taiwan, and would lead 
to more cost averted. 
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OBJECTIVES: To determine the cost-effectiveness of the second line treatment of 
advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI) comparing to docetaxel under health-care pro-
vider perspective. Only direct medical cost was considered. Outcomes included the 
patients’ survivals. METHODS: We collected data of aNSCLC patients treated at the 
Medical Oncology Unit during the year 2009 in a prospective manner. Patients were 
followed until death. Direct medical costs included medicine cost, laboratory cost, 
